000			03968nam a22003855i 4500
001			76262
003			ES-MaUEC
005			20230207040216.0
007			cr nn 008mamaa
008			140916s2014 gw s 000 0 eng d
020			_a9783319067520
024	7		_a10.1007/978-3-319-06752-0 _2doi
040			_aES-MaUEC
050		4	_aRC271.P74 _bR47 2014 EB
082	0	4	_a614.5999
245	0	0	_aResistance to Proteasome Inhibitors in Cancer : _bMolecular Mechanisms and Strategies to Overcome Resistance _cedited by Q. Ping Dou
260			_aCham, Switzerland _bSpringer International Publishing _c2014
300			_a1 recurso en línea (XI, 390 p.) _b55 ilustraciones, 51 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	1		_aResistance to Targeted Anti-Cancer Therapeutics _x2196-5501
505	0		_aProteasome inhibitors and lessons learned from their mechanisms of action and resistance in human cancer -- Resistance to proteasome inhibitors in multiple myeloma -- Overcoming bortezomib resistance: a review on the second generation proteasome inhibitor carfilzomib in the treatment of multiple myeloma -- Proteasome inhibitors in the treatment of multiple myeloma and amyloidosis -- Profiling bortezomib resistance in multiple myeloma: implications in personalized pharmacotherapy -- Targeting mantle cell lymphoma with a strategy of combined proteasome and histone deacetylase inhibition -- Pre-clinical studies on the molecular basis of bortezomib resistance and modalities to overcome resistance in hematological malignancies -- Overcoming inherent resistance to proteasome inhibitors in head and neck cancer: Challenges and new approaches -- Targeting the proteasome pathway for the treatment of solid tumors -- Oxidative stress and the proteasome: mechanism and the therapeutic relevance -- Proteotoxic stress and proteasome inhibitor efficacy and resistance -- Proteasome inhibitors versus E3 ligase inhibitors for cancer therapy -- Novel ubiquitin E3 ligases as targets for cancer therapy: Focus on breast cancer associated gene 2 (BCA2) -- The 26S proteasomal ATPases: structure, function, regulation and potential for cancer therapies -- Deubiquitinating enzymes as novel targets for cancer therapies.
520			_aThe book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume. This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.
942			_2lcc _cLE
988			_aEBOOK, EBSPRINGERrevisando
650		7	_aInhibidores de proteasas _9158773 _0comprobar BNE20012084273 _2embne
650		7	_aCáncer _xInvestigación _0comprobar BNE19901364217 _2embne _9182523
700	1		_aDou, Q. Ping _eeditor literario _0Local _985225
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-06752-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9783319067520
907			_a.b1281880x _b10-10-17 _c01-10-14
998			_am _a_alco _a_vill _b19-06-17 _cm _dz _eu _feng _ggw _h0
945			_aRC271 .P74 R47 2014 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11548022 _z06-04-17
999			_c76262 _d76262 _x1